Next-Generation Sequencing Analysis of ctDNA for the Detection of Glioma and Metastatic Brain Tumors in Adults

Jianfeng Liang,Wanni Zhao,Changyu Lu,Danni Liu,Ping Li,Xun Ye,Yuanli Zhao,Jing Zhang,Dong Yang

DOI: https://doi.org/10.3389/fneur.2020.00544

IF: 3.4

2020-08-21

Frontiers in Neurology

Abstract:Background and aims: The next-generation sequencing technologies and their related assessments of circulating tumor DNA in both glioma and metastatic brain tumors remain largely limited.Methods: Based largely on a protocol approved by the institutional review board at Peking University International Hospital, the current retrospective, single-center study was conducted. Genomic DNA was extracted from blood samples or tumor tissues. With the application of NextSeq 500 instrument (Illumina), Sequencing was performed with an average coverage of 550-fold. Paired-end sequencing was employed utilized with an attempt to achieve improved sensitivity of duplicate detection and therefore to increase the detection reliability of possible fusions.Results: A total of 28 patients (21 men and 7 women) with brain tumors in the present study were involved in the study. The patients enrolled were assigned into two groups, including glioma group (n = 21) and metastatic brain tumor group (n = 7). The mean age of metastatic brain tumor group (59.86 ± 8.85 y), (43.65 ± 13.05 y) reported significantly higher results in comparison to that of glioma group (45.3 ± 12.3 years) (P < 0.05). The mutant genes in metastatic brain tumor group included ALK, MDM2, ATM, BRCA1, FGFR1, MDM4 and KRAS; however, there were no glioma-related mutant genes including MGMT, IDH1, IDH2, 1p/19q, and BRAF et al. Interesteringly, only two patient (28.3%) was detected blood ctDNA in metastatic brain tumor group; In contrast, blood ctDNA was found in ten glioma patients (47.6%) including 1p/19q, MDM2, ERBB2, IDH1, CDKN2A, CDK4, PDGFRA, CCNE1, MET. The characterizations of IDH mutations in the glioma included IDH1 mutation (p.R132H) and IDH2 mutation (p.R172K). The mutation rate of IDH in tumor tissues was 37.06 ± 8.32%, which was significantly higher than blood samples (P < 0.05).Conclusion: The present study demonstrated that the mutant genes among glioma and metastatic brain tumors are shown to be different. Moreover, the ctDNAs in the metastatic brain tumors included ALK and MDM2, and glioma-related ctDNAs included 1p/19q and MDM2 followed by frequencies of ERBB2, IDH1, CDKN2A, CDK4, PDGFRA, CCNE1, MET. These ctDNAs might be biomarkers and therapeutic responders in brain tumor.

neurosciences,clinical neurology

What problem does this paper attempt to address?

### Problems the paper attempts to solve This paper aims to analyze circulating tumor DNA (ctDNA) through next - generation sequencing technology (Next - Generation Sequencing, NGS) to detect gene mutations in adult gliomas and metastatic brain tumors. Specifically, the main objectives of the study include: 1. **Identify gene mutations in different types of brain tumors**: - Compare the differences in gene mutations between primary gliomas and metastatic brain tumors. - Determine whether these mutations can be used as biomarkers for diagnosis and treatment. 2. **Evaluate the application of ctDNA in brain tumor detection**: - Detect brain - tumor - related gene mutations through ctDNA in blood samples, thereby providing a non - invasive detection method. - Evaluate the sensitivity and specificity of ctDNA detection, especially in different types of brain tumors. 3. **Explore the potential of ctDNA in dynamic monitoring of brain tumors**: - Monitor the progression of brain tumors and treatment responses by regularly collecting blood samples. - Evaluate the feasibility of ctDNA in real - time monitoring of tumor progression. ### Research background Brain tumors are a highly heterogeneous disease with a relatively high incidence and mortality rate. According to the World Health Organization (WHO) classification, brain tumors can be divided into primary gliomas and metastatic brain tumors. Traditional diagnostic methods such as clinical examinations, magnetic resonance imaging (MRI), and histopathological biopsies have certain limitations and are difficult to meet the needs of clinical practice. Therefore, it is particularly important to develop non - invasive or minimally invasive techniques to detect circulating tumor DNA (ctDNA). ### Methods The study conducted genomic analysis on blood samples and tissue samples from 28 brain - tumor patients based on NGS technology. The main steps include: 1. **Sample collection and processing**: - Extract ctDNA from the peripheral blood of patients. - Extract DNA from formalin - fixed paraffin - embedded (FFPE) tissue samples. 2. **Sequencing and data analysis**: - Use the Illumina NextSeq 500 instrument for sequencing with an average coverage depth of 550 - fold. - Perform data pre - processing, quality control, alignment, deduplication, and variation detection. - Use tools such as GATK and VarScan2 to analyze variation information and genotype information. 3. **Statistical analysis**: - Use SPSS software for statistical analysis, including the calculation of means and standard deviations, analysis of variance (ANOVA), t - tests, and chi - square tests. ### Results 1. **Patient characteristics**: - A total of 28 patients were included in the study, of which 21 were male and 7 were female. - The average age of primary glioma patients was 43.65 ± 13.05 years, and the average age of metastatic brain - tumor patients was 59.86 ± 8.85 years, with a significant difference (P < 0.05). 2. **Gene mutations**: - The mutated genes in metastatic brain tumors include ALK, MDM2, ATM, BRCA1, FGFR1, and KRAS. - The mutated genes in primary gliomas include MGMT, IDH1, IDH2, 1p/19q, BRAF, etc. - In primary gliomas, 47.6% of patients had ctDNA detected in their blood, while in metastatic brain tumors, only 28.3% of patients had ctDNA detected. 3. **IDH mutation characteristics**: - The frequencies of IDH1 mutation (p.R132H) and IDH2 mutation (p.R172K) in primary gliomas were relatively high. - The abundance of IDH mutations in tumor tissues was 37.06 ± 8.32%, which was significantly higher than that in blood samples (P < 0.05). ### Conclusions This study shows the differences in gene mutations between primary gliomas and metastatic brain tumors and discovers the potential application value of ctDNA in brain - tumor detection. The research results indicate that NGS technology can be used to distinguish between primary and metastatic brain tumors, and ctDN

Next-Generation Sequencing Analysis of ctDNA for the Detection of Glioma and Metastatic Brain Tumors in Adults

Transcriptomic Profiling Identifies a Nucleotide Metabolism-Related Signature with Prognostic Power in Gliomas

P1.01-18 Integrated Genomic and DNA Methylation Analyses of Non-Small Cell Lung Cancer Patients with Brain Metastases

Genomic Landscapes by Multiregion Sequencing Combined with Circulation Tumor DNA Detection Contribute to Molecular Diagnosis in Glioblastomas

P2.15-33 Evaluation of Liquid Biopsies for Molecular Profiling in Patients (pts) with Advanced NSCLC: What Happens after Panel Testing by NGS?

Abstract P2-02-06: Biomarker analysis by next generation circulating tumor DNA (ctDNA) sequencing in patients with advanced breast cancer

Comprehensive Molecular Characterization of Chinese Patients with Glioma by Extensive Next-Generation Sequencing Panel Analysis

Biom-48. Utility Of Circulating Tumor Dna (Ctdna) From Cerebrospinal Fluid (Csf) For Prognosis Of Patients With Recurrent High-Grade Glioma

Detection of Circulating Tumor DNA from Non‐small Cell Lung Cancer Brain Metastasis in Cerebrospinal Fluid Samples

The Landscape of Actionable Genomic Alterations by Next-Generation Sequencing in Tumor Tissue Versus Circulating Tumor DNA in Chinese Patients With Non-Small Cell Lung Cancer

Cerebrospinal fluid ctDNA testing shows an advantage over plasma ctDNA testing in advanced non-small cell lung cancer patients with brain metastases

Biom-61. Csf Ctdna Analysis Of Patients With Diffuse Gliomas Reveals Diagnostic Molecular Alterations

Clinical Application of Circulating Tumor DNA in the Genetic Analysis of Patients with Advanced GIST

Comprehensive Analysis of Genomic Alterations Detected by Next-Generation Sequencing-Based Tissue and Circulating Tumor DNA Assays in Chinese Patients with Non-Small Cell Lung Cancer

P2.01-107 Analysis of Mutation Detection by Ctdna on the Basis of Metastatic Sites in Lung Adenocarcinoma Patients

Abstract 3703: Utility of circulating tumor DNA (ctDNA) from cerebrospinal fluid (CSF) for prognosis of patients with recurrent high grade glioma

Genomic characterization of circulating tumor DNA from Chinese advanced small-cell lung cancer to reveal potential therapeutic opportunities.

ctDNA analysis in patients with cancer of unknown primary and its value in guiding targeted treatment when combined with predicted cancer types by 90-gene reverse-transcription polymerase chain reaction assay.

Technical progress in circulating tumor DNA analysis using next generation sequencing

Circulating Tumor DNA Identified by Targeted Sequencing in Advanced-Stage Non-Small Cell Lung Cancer Patients.

Utility Of Circulating Tumor Dna In Genomic Profiling Of Colorectal Cancer With Peritoneal Metastasis.